Introduction
The use of plants for medicinal purposes in traditional Chinese medicine and Japanese herbal medicine has been effective in the treatment of many diseases. The root and stem bark of Magnolia sp. has been used for centuries in the treatment of anxiety and nervous disorders, fever, gastrointestinal symptoms, and stroke 1 . One of the major chemical constituents of Magnolia sp. to which its therapeutic benefits are attributed is the phenolic compound honokiol 2 . Honokiol can be extracted from the root, stem bark, and seed cones of several magnolia species and has a number of pharmacological benefits including anti-thrombocytic, anti-bacterial, anti-inflammatory, and anxiolytic effects 3,4 5,6 .
Honokiol is known to possess potent anti-neoplastic and anti-angiogenic properties. In vitro studies revealed that honokiol inhibited cell proliferation and induced cytotoxicity in the human leukemia cell line HL-60 7 . Previous reports have demonstrated that honokiol induces apoptosis in numerous cell lines, including murine endothelial SVR cells, human leukemia MOLT 4B cells, human colorectal carcinoma RKO cells, and human squamous lung cancer CH27 cells [8] [9] [10] [11] . Honokiol has also been reported to act as an inhibitor of reactive oxygen species 5 , a property that may be of therapeutic benefit in certain neoplasias 12 . In vivo studies further support the observation that honokiol is a potent anti-neoplastic compound. Honokiol demonstrated significant inhibitory effects in the classical two-stage model for chemically induced skin carcinogenesis 13 . Moreover, honokiol exhibited anti-tumor activity in mice, as demonstrated by inhibition on the in vivo growth of SVR angiosarcoma cells in nude mice 8 .
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For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From B-CLL is a clinically heterogeneous disease characterized by the accumulation of CD5+ B lymphocytes with significant resistance to apoptosis and, therefore, prolonged survival. The impaired apoptosis that occurs in B-CLL is attributed to several mechanisms, including overexpression of Bcl-2 family members, impaired activity of cell death receptors, and/or overexpression of cytokines and angiogenic factors that support the survival of B-CLL cells [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Current treatment regimens employ alkylating agents, purine analogs, monoclonal antibodies or combinations thereof. Such combination therapies result in greater response rates than those seen with single agent-based therapy alone, but none of these therapies is curative. Thus, continued pre-clinical studies on innovative therapeutic strategies are warranted. The identification of new agents that interfere with the survival of B-CLL cells by promoting their apoptosis is one critical approach to improving therapeutic outcome.
Given the ability of honokiol to induce apoptosis in tumor cells, we investigated the in vitro efficacy of honokiol in primary B-CLL cells. We demonstrate that honokiol exhibits cytotoxic activity toward B-CLL cells and that B-CLL cells were more susceptible to the cytotoxic effects of honokiol compared to normal hematopoietic cells.
Honokiol-induced cytotoxicity was characterized by caspase-mediated programmed cell death, which was maintained in the presence of the pro-survival cytokine IL-4.
Moreover, honokiol potentiated the cytotoxicity of fludarabine, cladribine, and chlorambucil. These pre-clinical studies suggest that honokiol could be useful for the treatment of B-CLL.
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Materials and Methods

Cell Isolation, Culture, and Reagents
Peripheral blood was collected in heparin-coated tubes from patients fulfilling diagnostic criteria for B-CLL following informed consent. Mononuclear cells were isolated by Ficoll density-gradient centrifugation. Flow cytometric analysis of co-expression of CD5 and CD19 determined that the mean purity of the isolated B-CLL cells was 92% ± 3.9%
(range: 85.0%-97.7%). Normal peripheral blood mononuclear cells (PBMC) were obtained from donors following informed consent and isolated in the same manner.
Fresh and cryopreserved B-CLL cells were studied. The viability of fresh cells was determined by trypan blue counting and was 98.1-99%. For studies in which frozen cells were used, B-CLL cells were frozen in fetal bovine serum (FBS) containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. The viability of cryopreserved cells was determined by trypan blue counting immediately upon thawing. Only cells whose viability exceeded 93% (range: 93.4%-99%) were used in this study. B-CLL cells were cultured in RPMI-1640 containing 10% FBS. Honokiol was obtained from Wako Chemical Company (Tokyo, Japan), and its purity was determined to be a minimum of 99% by high performance liquid chromatography. Honokiol was solubilized in DMSO at a concentration of 10 mg/ml. substrate by flow cytometric analysis using the FL1 channel.
Reagents
Real-time PCR
Total cellular RNA was isolated using the RNEasy Mini kit (Qiagen, Valencia, CA).
cDNA was synthesized from 300 ng total RNA using the SuperScript First-Strand for 1 min. Gene expression was quantitated using the comparative C T method of relative quantification using 7500 System SDS software (Applied Biosystems, Foster City, CA).
The mean fold changes ± s.e.m. of the three replicates were calculated. 
IL-4 Studies
B-CLL cells were cultured at a density of 5 X 10 6 cells/ml in RPMI 160 containing 10%
FBS and incubated with 25 ng/ml IL-4. After 24 hours, 40 µM honokiol was added to cultures. After an additional 24 hours, apoptosis was analyzed using the Annexin V-FITC/PI staining method described above. Louis, Missouri) in the presence or absence of 25 µM honokiol. Cells were incubated for 24 hours and then viability was assessed on 100 µl of cell culture using the luminescence based assay as described above.
Statistical Analysis
The independent Student's t test was used for statistical significance between two groups and paired data were evaluated by the paired Student's t test. The P value was considered significant when it was less than 0.05.
Results
Honokiol-induced cytotoxicity toward B-CLL cells is dose-and time-dependent.
To determine whether honokiol can induce B-CLL cell death, CLL cells from 19 untreated patients with B-CLL (see Table 1 for clinical characteristics) were incubated in vitro with various concentrations of honokiol for 6-24 hours and assayed for viability using a luminescent-based ATP assay. Each patients' cells were sensitive to the cytotoxic effects of honokiol ( Figure 1A ). The concentration of honokiol that caused death of 50% of the cells (LC 50 ) after 6 hours of incubation with honokiol was 49 µM.
Exposure to honokiol for 24 hours resulted in an LC 50 of 38 µM. The viability of B-CLL cells treated with 40 µM honokiol for 24 hours was determined for each patient (Table 1) respectively. These data support the conclusion that B-CLL cells are more susceptible to honokiol-induced apoptosis compared to normal PBMCs.
Honokiol induces caspase-dependent apoptosis of B-CLL cells.
To determine whether honokiol-induced apoptosis was dependent upon caspase activation, B-CLL cells were cultured in the presence and absence of the broad-spectrum 
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To further characterize honokiol-induced apoptosis, we examined whether honokiol activates the extrinsic or intrinsic apoptotic pathway in B-CLL cells. To determine which apoptotic pathway honokiol activates, we examined patterns of proteolytic processing of caspases 8 and 9, the apical proteases in the extrinsic and intrinsic pathways, respectively, by Western analysis. Levels of procaspase 8 decreased, and levels of the cleaved, active form of caspase 8 accumulated within 6 hours of honokiol treatment ( Figure 2D ). Pro-caspase 8 levels continued to decrease, and levels of cleaved caspase 8 continued to increase through 24 hours of honokiol treatment. Levels of procaspase 9 also decreased upon honokiol treatment; however, this was not detectable
hours. These data suggest that both caspases 8 and 9 are activated by honokiol, but that caspase 8 activation precedes caspase 9 activation, which can be activated by caspase 8 activity in a feedback loop 25, 26 . The proteolytic processing patterns and kinetics are consistent with activation of the extrinsic pathway.
To further examine whether important pro-and anti-apoptotic regulatory proteins could be modulated by honokiol in B-CLL cells, we analyzed bcl-2 and bax levels by Western blotting. Bcl-2 is an anti-apoptotic regulatory protein that is overexpressed in B-CLL cells 14, 27 . Western blot analysis revealed that exposure of B-CLL cells to honokiol had no effect on bcl-2 levels ( Figure 2E ). In contrast, the expression of bax, a protein that can promote apoptosis, increases following honokiol treatment. The combination of only.
For expression and the inability to achieve complete remission has been reported, indicating that higher Mcl-1 protein expression is an indicator of adverse outcome for B-CLL patients 28 . In one study, Mcl-1 was the only protein among a panel of anti-apoptotic proteins studied found to be associated with chemoresistance in vitro and failure to achieve complete response in B-CLL patients 15 . Conversely, patients who achieved complete remission exhibited low Mcl-1 levels, and in vitro exposure to chemotherapeutic agents caused a reduction in its relative levels. Thus, it was important to perform in vitro studies as a first step toward determining whether honokiol could For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From expression is emerging as a prognostic determinant of outcome and response 42 . Our finding that honokiol overcomes the apoptosis resistance present in B-CLL cells at least in part by down-regulation of Mcl-1 bears potential significant clinical relevance.
Another clinically relevant observation of our study was that IL-4 does not protect against the pro-apoptotic effects of honokiol. IL-4 is a major survival factor for B-CLL cells and protects cells against spontaneous apoptosis in tissue culture. The pro-survival effect of IL-4 is thought to be due to its ability to up-regulate Bcl-2 protein levels in B-CLL cells in vitro 20, 43 . In the present study, cells were cultured for 24 hours with IL-4 to allow sufficient time to induce pro-survival effects before honokiol was added, yet honokiol remained active and could still induce apoptosis in the presence of the cytokine.
This is in contrast to other treatments, such as fludarabine, chlorambucil, and prednisone, whose cytotoxicity is diminished by IL-4 32 . Our findings suggest that the cytotoxic effects of honokiol may be able to overcome the supportive role of the tumor microenvironment, which provides cytokines and factors that support the survival of B-CLL cells.
An important observation of our study is that honokiol, perhaps by lowering the apoptotic threshold, enhances the cytotoxic effects of other chemotherapeutic agents commonly used in the treatment of B-CLL. This reduced viability was evident when honokiol was used in combination with nucleoside analogs or with chlorambucil. This suggests that the combining a low dose of honokiol with other anticancer drugs may be a potential therapeutic strategy.
Further investigation is needed to determine whether honokiol can be applied clinically for the treatment of B-CLL; however, pharmacokinetic studies in animals and only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From studies from clinical trials investigating herbal remedies that contain honokiol suggest that honokiol may be a safe and potent chemotherapeutic agent. Pharmacokinetic studies in mice revealed that honokiol is readily absorbed and maintained in the plasma for over 10 hours 44 . The plasma concentration attainable in mice administered 10 mg/kg or 250 mg/kg honokiol was 5 µg/ml and 1000 µg/ml, respectively, which corresponds to concentrations that approximate or exceed the levels that induce cytotoxicity of tumor cells in vitro 44, 45 . Administration of 3 mg/day honokiol in mice (i.e., 120 mg/kg) for 30 days was well tolerated 8 . Honokiol is one of the active compounds in the Japanese herbal medicine, Saiboku-to, which has traditionally been consumed as a tea for its antianxiety effects and has undergone clinical evaluation in Japan for the treatment of asthma 46 . Symptomatic improvement was reported in the honokiol-treated asthma patients;
however, higher quality clinical trials that address both the efficacy as well as the potential adverse effects that occur with the use of herbal medicines are needed.
In conclusion, honokiol may be an effective therapeutic agent in the treatment of B-CLL, and thus clinical studies with honokiol may be appropriate. Given its ability to overcome apoptotic resistance, honokiol may also be effective in other hematopoietic malignancies. Further investigation of honokiol in mouse models of B-CLL and other leukemias will contribute to additional understanding of its in vivo activity toward malignant cells and its potential toxicity toward normal tissues. Finally, efforts to elucidate the molecular target of honokiol are ongoing and will aid in its clinical application.
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